ATE332708T1 - Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält - Google Patents

Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält

Info

Publication number
ATE332708T1
ATE332708T1 AT01941917T AT01941917T ATE332708T1 AT E332708 T1 ATE332708 T1 AT E332708T1 AT 01941917 T AT01941917 T AT 01941917T AT 01941917 T AT01941917 T AT 01941917T AT E332708 T1 ATE332708 T1 AT E332708T1
Authority
AT
Austria
Prior art keywords
pde4 inhibitor
cancer treatment
composition containing
treatment composition
antineoplastic agent
Prior art date
Application number
AT01941917T
Other languages
English (en)
Inventor
Stephen Thomas Davis
Inderjit Kumar Dev
Ronna Ellen Dornsife
John Gordon Gray
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE332708T1 publication Critical patent/ATE332708T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01941917T 2000-06-06 2001-06-04 Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält ATE332708T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20984600P 2000-06-06 2000-06-06

Publications (1)

Publication Number Publication Date
ATE332708T1 true ATE332708T1 (de) 2006-08-15

Family

ID=22780552

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01941917T ATE332708T1 (de) 2000-06-06 2001-06-04 Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält

Country Status (7)

Country Link
EP (1) EP1289557B1 (de)
JP (1) JP2003535148A (de)
AT (1) ATE332708T1 (de)
AU (1) AU2001275228A1 (de)
DE (1) DE60121440T2 (de)
ES (1) ES2267778T3 (de)
WO (1) WO2001093909A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03005014A (es) 2000-12-06 2004-09-10 Robert J Hariri Metodo para recolectar celulas madres de la placenta.
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
AU2002251935B2 (en) 2001-02-14 2007-11-29 Celularity Inc. Post-partum mammalian placenta, its use and placental stem cells therefrom
EP2338983B1 (de) 2001-02-14 2015-10-07 Anthrogenesis Corporation Regeneration und Repopulation von dezellularisierten Geweben und Kadaverorganen durch Stammzellen.
WO2002094321A1 (en) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
KR20040007583A (ko) * 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 연골 질환의 재생치료용 조성물
PT1908463E (pt) * 2001-12-14 2011-12-19 Merck Serono Sa Método para induzir a ovulação utilizando um modulador de nível camp não polipeptídico
CA2481385A1 (en) * 2002-04-12 2003-10-23 Celgene Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
AU2003298775B2 (en) 2002-11-26 2008-07-17 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
PL378247A1 (pl) * 2003-01-14 2006-03-20 Altana Pharma Ag Inhibitory PDE4 w terapii nowotworów komórek limfoidalnych
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
EP1957633B1 (de) 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunmodulation unter verwendung von plazentastammzellen
AU2006332679A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
KR20180105266A (ko) 2005-12-29 2018-09-27 안트로제네시스 코포레이션 태반 줄기 세포 집단
CN103356710A (zh) 2007-02-12 2013-10-23 人类起源公司 利用胎盘干细胞治疗炎性疾病
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
EP2203176B1 (de) 2007-09-28 2014-11-26 Anthrogenesis Corporation Tumorsuppression mit menschlichem plazentaperfusat und menschlichen natürlichen killerzellen eines zwischenproduktes aus der plazenta
NZ591292A (en) 2008-08-20 2012-10-26 Anthrogenesis Corp Improved cell composition and methods of making the same
WO2010059828A1 (en) 2008-11-19 2010-05-27 Anthrogenesis Corporation Amnion derived adherent cells
CA2787992A1 (en) 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
PL2556145T3 (pl) 2010-04-07 2017-02-28 Anthrogenesis Corporation Angiogeneza z zastosowaniem łożyskowych komórek macierzystych
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
DK2714059T3 (en) 2011-06-01 2019-01-21 Celularity Inc TREATMENT OF PAIN WHEN USING PLACENT STAM CELLS
US20150157584A1 (en) * 2012-06-11 2015-06-11 The J. David Gladstone Institutes Inhibitors of hippo-yap signaling pathway
EP3622960A1 (de) 2013-02-05 2020-03-18 Celularity, Inc. Natürliche killerzellen aus plazenta
US11052101B2 (en) 2019-03-25 2021-07-06 National Guard Health Affairs Methods for treating cancer using purine analogs by depleting intracellular ATP

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
JP2002500188A (ja) * 1998-01-08 2002-01-08 ザ・ユニバーシティ・オブ・バージニア・パテント・ファウンデーション A2aアデノシンレセプター作動因子
EP1067919A1 (de) * 1998-03-28 2001-01-17 THE ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA Dfmo und sulindac in krebs-präventiven kombinationen
AU6047099A (en) * 1998-09-24 2000-04-10 Boston Medical Center Corporation Compositions and methods for the treatment of chronic lymphocytic leukemia
EP1278519A4 (de) * 2000-04-12 2003-05-07 Cell Pathways Inc Behandlungsmethode eines patienten mit neoplasie durch behandlung mit einem topoisomerase i inhibitor
EP1188438A1 (de) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmazeutische Zusammensetzungen zur Vorbeugung oder Behandlung von mit IL-12 Überproduktion assozierten Erkrankungen

Also Published As

Publication number Publication date
ES2267778T3 (es) 2007-03-16
EP1289557B1 (de) 2006-07-12
JP2003535148A (ja) 2003-11-25
WO2001093909A2 (en) 2001-12-13
AU2001275228A1 (en) 2001-12-17
DE60121440T2 (de) 2007-06-28
EP1289557A2 (de) 2003-03-12
DE60121440D1 (de) 2006-08-24
WO2001093909A3 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
DE60121440D1 (de) Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält
IL165267A (en) A drug comprising a mixture of an amino phospholipid antibody and a selected antiviral agent or antiviral vaccine conjugate, and an amino phospholipid binding antibody for use in the treatment or prevention of viral infections or diseases
CR7693A (es) Terapia de combinacion para enfermedades hiperproliferativas
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
PT932402E (pt) Metodo de utilizacao de inibidores de ciclooxigenase-2 no tratamento e prevencaode neoplasia
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
WO2001051043A3 (en) Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
BR9709942A (pt) Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo
NO20041598L (no) Fremgangsmater for behandling eller profylakse av vaskulaer betennelse ved anvendelse av sterolabsorpsjonsinhibitor(er)
DE60216300D1 (de) Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
DE69940951D1 (de) Nd wachstumshemmende mittel
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
TR199901104T2 (xx) Farmas�tik bile�ikler.
TR200401669T1 (tr) Neoplastik hastalıkların tedavisi için metarix-metalloproteinazları önleyen kompozisyon.
BR0201862A (pt) Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos
BR9808221A (pt) Método de tratamento de tumor.
WO2003013554A3 (en) Aromatase inhibitors from broussonetia papyrifera
WO2002062334A3 (en) Cancer chemopreventative compounds and compositions and methods of treating cancers
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties